Meta-Analysis of Albumin vs. Crystalloid for ARDS Mortality

5 publications, including 3 randomized controlled trials and 2 non-randomized studies, were analyzed to evaluate albumin administration in adult ARDS patients. The analysis found overall mortality was lower in the albumin group (33.2%) than the crystalloid group (44.9%), with hyper-oncotic albumin showing potential benefit in non-randomized studies. Results indicate a need for further high-quality RCTs to confirm these findings.

Use Cases

• Evaluating 28-day mortality outcomes for different fluid replacement therapies in ARDS.
• Assessing the impact of albumin concentration (hyper-oncotic vs. iso-oncotic) on patient oxygenation.
• Comparing treatment effects between randomized controlled trials and non-randomized study designs.
• Informing the design of future clinical trials through trial sequential analysis results.

Strengths

• Includes data from 5 distinct publications, aggregating results from 292 patients in the albumin group and 296 in the crystalloid group.
• Employs subgroup analysis for hyper-oncotic (≥20%) and iso-oncotic (4%-5%) albumin concentrations.
• Uses trial sequential analysis to assess the need for further research, mitigating random errors.

Limitations

• Column names and row counts are not specified in the provided metadata, limiting understanding of the dataset's internal structure.
• The analysis incorporates both RCTs and non-randomized studies, which may introduce heterogeneity in evidence quality.
• The dataset's freshness is unclear; the last update date (2026-03-24) is a future date, suggesting a potential metadata error.

Provenance

Source

Yan-Jie Zhang

Collection Method

Systematic review and meta-analysis of trials sourced from PubMed, Science Direct, Scopus, Web of Science, and Cochrane Central up to December 12, 2024.

Time Range

Literature search covered studies up to December 12, 2024.

Freshness

Last updated date is listed as 2026-03 24, which is a future date and may be incorrect.

Geography

null